Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

Pembrolizumab, a programmed death 1 inhibitor, demonstrated promising single-agent activity in untreated patients with various cancer types. The phase II KEYNOTE-427 study evaluated efficacy and safety of single-agent pembrolizumab in treatment-naive patients with advanced clear cell renal cell carc...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of clinical oncology Ročník 39; číslo 9; s. 1020
Hlavní autoři:	McDermott, David F, Lee, Jae-Lyun, Bjarnason, Georg A, Larkin, James M G, Gafanov, Rustem A, Kochenderfer, Mark D, Jensen, Niels Viggo, Donskov, Frede, Malik, Jahangeer, Poprach, Alexandr, Tykodi, Scott S, Alonso-Gordoa, Teresa, Cho, Daniel C, Geertsen, Poul F, Climent Duran, Miguel Angel, DiSimone, Christopher, Silverman, Rachel Kloss, Perini, Rodolfo F, Schloss, Charles, Atkins, Michael B
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 20.03.2021
Témata:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - pathology Female Follow-Up Studies Humans Kidney Neoplasms - drug therapy Kidney Neoplasms - pathology Male Middle Aged Non-Randomized Controlled Trials as Topic Prognosis Survival Rate
ISSN:	1527-7755, 1527-7755
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!